Novoic develops AI-based speech analysis software that detects subtle cognitive impairments and Alzheimer's neuropathology through automated audio-verbal assessments. This technology provides scalable access to early detection, significantly increasing the identification of mild cognitive impairment in underserved communities across over 50 medical centers.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AEFPA+1Founders
Product
Problem
Early detection of cognitive impairment and Alzheimer's disease is crucial for effective treatment, but current methods often lack scalability and accessibility, particularly in underserved communities. Traditional cognitive assessments can be time-consuming, require specialized personnel, and may not be readily available to all populations. This results in delayed diagnoses and limited opportunities for early intervention.
Solution
Novoic offers an AI-powered speech analysis platform designed to detect subtle cognitive changes indicative of early-stage Alzheimer's disease. The software utilizes automated audio-verbal assessments that can be administered on any smart device, enabling scalable and remote testing. By analyzing speech patterns, Novoic's algorithms identify clinically relevant biomarkers associated with cognitive decline and Alzheimer's neuropathology. The platform provides AI-assisted triage, helping clinicians identify individuals who may benefit from further evaluation. Novoic's technology aims to improve access to early detection, facilitate timely intervention, and support clinical research in diverse populations.
Target Audience
The primary target audience includes medical centers, research institutions, and clinicians focused on early detection and management of Alzheimer's disease, particularly those serving underserved communities.
Features
- AI-driven analysis of speech patterns to detect subtle cognitive impairments
- Automated audio-verbal assessments accessible on any smart device
- Algorithms trained on diverse datasets to improve robustness and reduce bias
- Prediction of amyloid PET positivity comparable to plasma tests
- AI-assisted triage for patient screening and inclusion
- Dashboard for managing digital screening and monitoring at scale
- Flexible integration options with SDKs and hosted versions
- HIPAA/GDPR compliance and automated backups for data privacy and security